6. パーキンソン病 Parkinson disease Clinical trials / Disease details

臨床試験数 : 2,298 / 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

5 trials found

diseases per page:

Showing 1 to 5 of 5 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03146130 (ClinicalTrials.gov)	July 5, 2018	3/5/2017	Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders	Study of the Efficacy of N-acetylcysteine(NAC) on Impulse Control Disorders (TCI) Induced by Dopamin ...	Impulse Control Disorder;Parkinson	Biological: Variation of behaviors of Parkinson's disease	Centre Hospitalier Universitaire, Amiens	NULL	Unknown status	18 Years	N/A	All	70	Phase 3	France
2	NCT03104725 (ClinicalTrials.gov)	September 25, 2017	4/4/2017	Does N-AcetylcysteineDecrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Diseas ...	Does N-AcetylcysteineDecrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Diseas ...	Parkinson Disease;Cerebrospinal Fluid	Drug: N-Acetylcysteine;Procedure: Lumbar Puncture;Radiation: Fluoroscopy	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Terminated	18 Years	N/A	All	6	Phase 1	United States
3	NCT02212678 (ClinicalTrials.gov)	September 2014	4/8/2014	Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease	Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease	Parkinson Disease	Drug: N-acetylcysteine capsule	University of Minnesota	Parkinson's Disease Society of the United Kingdom	Completed	18 Years	N/A	All	8	Phase 2	United States
4	NCT01470027 (ClinicalTrials.gov)	January 2012	4/11/2011	N-Acetylcysteine for Neuroprotection in Parkinson's Disease	N-Acetylcysteine for Neuroprotection in Parkinson's Disease	Parkinson Disease	Drug: N-acetylcysteine;Drug: Placebo	Weill Medical College of Cornell University	National Institute on Aging (NIA)	Completed	50 Years	75 Years	All	50	Phase 1/Phase 2	United States
5	NCT01427517 (ClinicalTrials.gov)	July 2011	30/8/2011	Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease	Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease	Parkinson's Disease;Gaucher's Disease	Drug: N-acetylcysteine	University of Minnesota	Rare Diseases Clinical Research Network;National Center for Advancing Translational Science (NCATS); ...	Completed	18 Years	N/A	All	9	Phase 1	United States

First Previous1Next Last